Dishman Pharma rises 20% on USFDA approval for cancer drug

Shares of Dishman Pharmaceuticals & Chemicals locked at 20 percent upper circuit on Tuesday on the back of USFDA approval for its cancer drug.

The company has received United States Food and Drug Administration (USFDA) approval for cancer drug Zejula Capsules, for Tesaro Inc.

"There are several products pending for approval and will be in talks with Tisaro for further action. It is tough to predict revenue potential from Zejula approval," said JR Vyas, CMD of Dishman Pharma.

At 09:22 hrs Dishman Pharmaceuticals & Chemicals was quoting at Rs 278.20, up Rs 46.35, or 19.99 percent.

It has touched a 52-week high of Rs 278.20.

There were pending buy orders of 154,858 shares, with no sellers available.